Business
GeneDx Announces Evolution of Executive Leadership Team
Melanie Duquette joining team as Chief Growth Officer to drive commercial excellence, Jennifer Brendel to take new role as Chief of Corporate Affairs
About this update from Genedx Holdings Corp.
[{"type":"text","content":"Melanie Duquette joining team as Chief Growth Officer to drive commercial excellence, Jennifer Brendel to take new role as Chief of Corporate Affairs amplifying the GeneDx brand and leadership platform\nSTAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS) a leader in delivering improved health outcomes through genomic and clinical insights, today announced the expansion and evolution of its executive leadership team with the appointment of Melanie Duquette as Chief Growth Officer and Jennifer (Jen) Brendel as Chief of Corporate Affairs. Both executives will report to Katherine Stueland, CEO and President, and will collaborate in continuing to strengthen GeneDx’s market leading position in genomic interpretation and health insights. Bringing nearly 20 years of genomic industry experience, in her role as Chief Growth Officer, Melanie will be responsible for the company’s overall growth strategy and will lead the sales, market access, clinician marketing and client services functions. Melanie joins GeneDx from Invitae where she spent the past decade driving commercial growth strategies to expand utilization of genetic testing. Most recently, she served as the Head of US Sales for Invitae, leading a sales and business development organization of more than 200 people and executing a commercial strategy that shifted the team towards profitable growth with a focus on increased ASPs. Prior to that, she led the company’s entry and rapid expansion into more than 100 international markets. “Over the past two years, our goal has been to drive utilization of our industry-leading whole exome and genome sequencing testing to help deliver more comprehensive and definitive diagnoses to as many patients as possible. We continue to deliver on that goal, and we are thrilled to add Melanie’s leadership and talents as we enter a new chapter of commercial success,” said Stueland. “Critically important to our mission is amplifying the GeneDx brand and commitment to clinical leadership across all constituents – current and future customers, patient advocates, policymakers, investors and media – and Jen can now help us ramp up a necessary part of our long-term growth strategy. The combined expertise and passion of these two leaders will ensure GeneDx realizes the next chapter of growth and brand transformation and accelerates the adop...